Identification of TAK-756, A Potent TAK1 Inhibitor for the Treatment of Osteoarthritis through Intra-Articular...

Area of Science:

• Pharmacology
• Biochemistry
• Rheumatology

Background:

• Osteoarthritis (OA) is a prevalent degenerative joint disease impacting over 500 million individuals globally.
• Currently, no approved disease-modifying treatments exist for OA.
• Transforming growth factor β-activated kinase 1 (TAK1) is identified as a promising molecular target for OA due to its anti-catabolic and anti-inflammatory roles.

Purpose of the Study:

• To develop novel transforming growth factor β-activated kinase 1 (TAK1) inhibitors.
• To optimize inhibitors for intra-articular injection, achieving high local drug concentrations and minimizing systemic toxicity.
• To enhance selectivity against related kinases like interleukin-1 receptor-associated kinases 1 and 4 (IRAK1/4).

Main Methods:

• Utilized structure-based design for inhibitor development.
• Modified physicochemical properties, including solubility and lipophilicity, for intra-articular delivery.
• Assessed selectivity against IRAK1/4 kinases.

Main Results:

• Developed TAK1 inhibitors with physicochemical properties suitable for intra-articular injection.
• Achieved high and sustained free drug exposure within the joint.
• Discovered TAK-756, a potent TAK1 inhibitor with improved selectivity over IRAK1/4 and favorable intra-articular pharmacokinetics.

Conclusions:

• TAK-756 demonstrates potential as a targeted therapy for osteoarthritis.
• The developed inhibitors offer a promising strategy for localized OA treatment, balancing efficacy and safety.
• Optimized physicochemical properties are crucial for effective intra-articular drug delivery in OA management.